Provides an overview and analysis of public funding of CER and the desirability and feasibility of incentivizing additional CER in the private sector. […]
How Comparative Effectiveness Feeds into Cost-Benefit Analysis by Kevin D. Frick PhD
The author relates CER to CBA, and discusses why CER research design is easier to translate into CBA than randomized controlled trials. […]
The Promise of Comparative-Effectiveness Research: Empowering Patients and Providers
[…]
AHEOR Media Library
PowerPoint Presentation by Dr. Joe Jackson,Applied Health Outcomes Research at Thomas Jefferson University. Proponents of Comparative Effectiveness Research (CER) hope to challenge conventional thinking in evidence-based medicine, observational research design, patient-centered aspects in medical […]
The Problems of Comparative Effectiveness Research
Advocates of CER often say their goal is to find and encourage what is best for patients, and certainly CER can be used in this way. But when the data gathered is used by government agencies to lower spending - such as by favoring older, cheaper drugs over newer, more expensive ones, as has been the […]
Comparative Effectiveness Analysis Using Simulated Treatment Comparison, PPT by L. Eckert
Presentation at ISPOR Europe, Nov. 2011 by Laurent Eckert, PhD, sanofi-aventis R&D, Massy, France […]
What Did Our Panelists Say at ISPOR on RCTs vs. Observational Studies?
Insight into the reasons for choosing one type of comparative effectiveness research study design over another. (Source: 5/24, National Pharmaceutical Council: E.V.I.dently Today) […]
Designing Better Comparative Effectiveness Research, PPT by R. Gliklich
Presentation at ISPOR Europe, Nov. 2011 by Richard Gliklich, MD, President & CEO, Outcome, Cambridge, MA, USA; Newell McElwee, PharmD, MSPH, Exec Director, US Outcomes Research, Merck , North Wales, PA, USA; Donna Messner, PhD, Senior Project Manager, Center for Medical Technology Policy, […]
Comparative Effectiveness Research: Evaluating the Flashy New Car(e)
Why do we expect government to pay for drugs and a whole menu of medical interventions that are no better at securing health than the older alternatives they seek to replace? The burden of evidence must be on innovation to explicitly prove its worth...Without research into the comparative […]
Comparative Effectiveness Research Primer Presentation.
Comparative Effectiveness Database
The National Patient Advocate Foundation has launched a comparative-effectiveness research database (PDF) that compiles research funded by the National Institutes of Health and the Agency for Healthcare Research and Quality...The database was launched with information on 224 NIH research projects; a […]
GRACE Principles: good practice for the design, conduct, analysis, and reporting of observational CER studies
Designed as a set of high-level questions, the GRACE Principles address good practice for the design, conduct, analysis, and reporting of observational CER studies. These principles may be expanded to provide more detail and/or to address special applications. […]
FDAs Initial CER Studies to Develop Trial Designs and Analytic Software
Examination of Data, Analytical Issues and Proposed Methods for Conducting Comparative Effectiveness Research Using “Real-World Data”.
JMCP Supplement. Includes Ten Commandments for CER, secondary data structures, stat issues, developing collaborative study protocol, and more. […]
Hierarchies of Evidence for Comparative Effectiveness – Reinforced by Unequal Quality of Publications?
Observational Methods in Comparative Effectiveness Research
Comparative effectiveness research (CER) may be defined informally as an assessment of available options for treating specific medical conditions in selected groups of patients. In this context, the most prominent features of CER are the various patient populations, medical ailments, and treatment […]
How Physicians Can Drive Comparative-effectiveness Research: Lessons from New Zealand
This role and how physicians might be involved in comparative-effectiveness research are important considerations. As front-line service providers, physicians have a considerable stake in how comparative-effectiveness research mechanisms are constructed, in leading collegial buy-in to associated […]
O Say Can You C(ER) – An Inventory Of Comparative Effectiveness Research Capacity In The HMO Research Network
The HMO Research Network (HMORN) is uniquely positioned to conduct Comparative Effectiveness Research (CER). The 2009 health care reform debate; Recovery Act legislation and funding mandates; the Institute of Medicine (IOM) report of Initial National Priorities for Comparative Effectiveness Research […]
Matters Related to Creating New Clinical Trial Designs and Statistics for CER
Presentation by Sheldon Greenfield, MD, Health Policy Research Institute, University of California, Irvine, November 17, 2010 […]
Modeling Good Research Practices (The Good, The Bad and The Ambiguous) Presentation by Jaime Caro
ISPOR Special Interest Group & Task Force Forum […]
Using Science to Improve the Nation’s Health System: The Case of Comparative Effectiveness Research Presentation
National Institute for Clinical Excellence and its value judgments
Article on the early formation of NICE […]
Clinical Trial Simulations With Mathematical Models: Applications to Generate Comparative Effectiveness Research (PPT Presentation)
Presentation by Badri Rengarajan, M.D., Archimedes […]
Study examines UK’s NICE as model producer of HTA
GfK HealthCare, one the largest providers of fully integrated custom health care marketing research in the world, announced today the undertaking of a first-ever research study aimed at examining the UK's National Institute for Health and Clinical Excellence (NICE) as a model producer of Health […]
Why observational studies should be among the tools used in comparative effectiveness research (Presentation)
Exploring Unintended Effects of FDA Diabetes Guidelines – Alogliptin Case Study
Pharma pricing and market access case study […]
Examining the Impact of Comparative Effectiveness Research and EVA Data on Health Plan Decision-Making
Presentation by David Gregory, Executive Vice President, Presscott Associates […]
Reimbursement and value-based pricing: stratified cost-effectiveness analysis may not be the last word
During recent discussions, it has been argued that stratified cost-effectiveness analysis has a key role in reimbursement decision-making and value-based pricing (VBP). It has previously been shown that when manufacturers are price-takers, reimbursement decisions made in reference to stratified […]
ISPOR Global Health Care Systems Road Map
AHRQ
This fact sheet describes awards made by the Agency for Healthcare Research and Quality (AHRQ) in Fiscal Year (FY) 2010 to support trainees who are focusing on comparative effectiveness research. Funding to support these projects was provided through the American Recovery and Reinvestment of 2009. […]
